Bharat Biotech Covaxin rolling data to start in July: WHO

Published On 2021-06-30 06:34 GMT   |   Update On 2021-06-30 06:34 GMT
Advertisement

Hyderabad: Taking the approval process ahead, World Health Organisation (WHO) which is currently approached by Bharat Biotech for an Emergency Use Listing of its COVID-19 vaccine Covaxin, has said pre-submission meeting for it was held and the "Rolling Data will starting in July."

The information was provided in the WHO website in the Status of COVID-19 vaccines within WHO EUL-PQ evaluation process document. Emergency Use Listing (EUL) is a procedure to streamline the process by which new or unlicensed products can be used during public health emergencies, WHO guidelines said.

Advertisement

Meanwhile, stating that its COVID-19 vaccine Covaxin adheres to international standards, Bharat Biotech''s joint managing director Suchitra Ella on Tuesday said external timelines are in the company's hands.

"Covaxin will cross new frontiers, adhering highest international regulatory guidelines. A new vaccine from (India) is all set to make history once again, with proven data, safety & quality. We stand committed to deliver no matter what, external timelines not in our control," Ella tweeted.

Her tweet assumes significance in the wake of the company trying to get EUL from the WHO even as its US partner Ocugen preparing to get US Food and Drug Administrations nod to use the jab in that country.

Read also: Bharat Biotech, WHO pre-submission meeting for Covaxin EUL on June 23

Ella also tweeted a table of states and cities in which Covaxin is currently available.

It said the jab is used in 27 cities in 18 states.

Read also: Reports on submitting Covaxin phase 3 data to WHO incorrect, lack any evidence: Bharat Biotech



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News